RESUMEN
Mendelian Susceptibility to Mycobacterial Disease (MSMD) is a rare syndrome with infections-among other complications-after Bacillus Calmette-Guerin (BCG) vaccination in children. We focused on the IL-12/IFN-γ pathway to identify new mutations in our patients. This study included 20 patients by vulnerability to mycobacteria and clinical manifestations of severe, recurrent infections. Blood samples were activated with BCG, BCG + IL-12 and BCG + IFN-γ. Cytokine levels were analyzed by ELISA. Measurements of IL-12Rß1 and IL-12Rß2 on the surface of peripheral blood mononuclear cells were performed by flow cytometry. To detect genetic defects, next-generation sequencing was performed by Thermo Fisher immunodeficiency panel. Flow cytometry analysis of 20 patients indicated reduction in IL-12R (ß1/ß2) expression in seven patients who showed incomplete production of IFN-γ by ELISA. In the patient with reduced IL-12 production, IFN-γR and IL-12R (ß1/ß2) expression levels were normal. Mutation analysis showed three previously reported mutations, two novel mutations in IL-12 R (ß1/ß2), and one previously reported mutation in IL-12.
Asunto(s)
Leucocitos Mononucleares/inmunología , Mutación , Mycobacterium bovis/inmunología , Receptores de Interleucina-12/genética , Tuberculosis/genética , Femenino , Citometría de Flujo , Humanos , Lactante , Subunidad p35 de la Interleucina-12/genética , Subunidad p40 de la Interleucina-12/genética , Masculino , Receptores de Interferón/genética , Receptores de Interleucina-12/análisis , Transducción de Señal , Receptor de Interferón gammaRESUMEN
BACKGROUND: Immune cell infiltration associated with tumor capsule disruption and tumor budding has been shown to reflect invasiveness, metastasis, and unfavorable prognosis in colorectal cancer. We investigated the influence of tumor budding on prognosis and its association with the immune microenvironment in lung adenocarcinoma. METHODS: Tumor slides from resected stage I lung adenocarcinomas were reviewed (n = 524 and n = 514, for training and validation cohorts, respectively) for assessment of tumor budding. CD3+ and forkhead box P3+ (FoxP3+) lymphocytes, CD68+ macrophages, IL-7 receptor, and IL-12 receptor ß2 were analyzed using tissue microarrays constructed from tumor and stroma. Probability of recurrence was calculated using the competing risks method. RESULTS: In the training cohort, risk of recurrence for high-grade tumor budding was higher than it was for low-grade tumor budding (32% vs 12%, P < .001), which was confirmed in the validation cohort (P = .005). Tumor budding stratified the risk of recurrence for acinar-predominant (22% vs 9%, P < .001), papillary-predominant (22% vs 13%, P = .045), and solid-predominant (39% vs 19%, P = .022) tumors. Tumor budding was associated with higher stromal FoxP3+ lymphocyte infiltration, higher stromal FoxP3/CD3 risk index, higher tumoral and stromal CD68+ macrophage infiltration, and IL-7 receptor overexpression (P < .001, all associations). Tumor budding remained independently associated with recurrence on multivariate analysis (hazard ratio, 1.61; P = .008). CONCLUSIONS: Tumor budding is an independent prognostic factor of stage I lung adenocarcinoma and correlates with the protumor immune microenvironment. Our findings advocate investigating tumor-immune cell interactions at the invading edge as a biologic driver of tumor aggressiveness.
Asunto(s)
Adenocarcinoma/inmunología , Adenocarcinoma/patología , Biomarcadores de Tumor/análisis , Neoplasias Pulmonares/patología , Recurrencia Local de Neoplasia/inmunología , Recurrencia Local de Neoplasia/patología , Adulto , Anciano , Anciano de 80 o más Años , Antígenos CD/análisis , Antígenos de Diferenciación Mielomonocítica/análisis , Complejo CD3/análisis , Femenino , Factores de Transcripción Forkhead/análisis , Humanos , Inmunohistoquímica , Linfocitos Infiltrantes de Tumor/inmunología , Linfocitos Infiltrantes de Tumor/metabolismo , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Pronóstico , Receptores de Interleucina-12/análisis , Receptores de Interleucina-7/análisis , Estudios Retrospectivos , Medición de Riesgo , Factores de Riesgo , Tasa de Supervivencia , Análisis de Matrices Tisulares , Microambiente TumoralRESUMEN
OBJECTIVE: This study evaluated the potential of interleukin 12 receptor beta 2 and tumor necrosis factor receptor superfamily member 8 as diagnostic biomarkers of oral lichen planus (OLP). MATERIALS AND METHODS: The mRNA expression of IL12RB2 and TNFRSF8 in FFPE OLP samples (OLP group, n = 38) were investigated with quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) analysis and compared to those of chronic non-specific mucositis (Non-OLP group, n = 25) and normal mucosa (Normal group, n = 18). Predictive modeling of the expression of IL12RB2 and TNFRSF8 was constructed using support vector machine (SVM), random forest (RF), linear discriminant analysis (LDA), neural network (NN) and naive Bayes (NB) methods. RESULTS: Normalized expression of IL12RB2 in the OLP group (3.78 ± 1.67) was significantly higher than the Normal group (1.97 ± 1.12), but lower than the Non-OLP group (6.86 ± 1.67). TNFRSF8 gene expression in the OLP group (7.46 ± 1.51) was significantly higher than the Normal group (2.90 ± 1.61), but no significant difference was found between the OLP and Non-OLP groups. The ratio of IL12RB2/TNFRSF8 in the OLP group (0.52 ± 0.23) was significantly lower than the Normal group (0.74 ± 0.39) and the Non-OLP group (1.07 ± 0.38). In the predictive modeling, the area under receiver operating characteristic (ROC) curves (AUC) ranged from 0.83-0.92 and their accuracy was higher than 0.75 in all methods. CONCLUSIONS: The IL12RB2/TNFRSF8 ratio can be a useful diagnostic tool for OLP.
Asunto(s)
Antígeno Ki-1/análisis , Liquen Plano Oral/metabolismo , Receptores de Interleucina-12/análisis , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Área Bajo la Curva , Teorema de Bayes , Biomarcadores/análisis , Análisis Discriminante , Femenino , Predicción , Humanos , Liquen Plano Oral/patología , Modelos Lineales , Masculino , Persona de Mediana Edad , Mucosa Bucal/química , Mucosa Bucal/patología , Redes Neurales de la Computación , Curva ROC , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodos , Estomatitis/metabolismo , Estomatitis/patología , Adulto JovenRESUMEN
PURPOSE: Mounting evidence suggests that tumor-infiltrating immune cells have prognostic value for patients with solid organ malignancies. Our aim was to investigate the prognostic significance of the immune microenvironment in patients with stage I lung adenocarcinoma (ADC). PATIENTS AND METHODS: Using tissue microarray and immunohistochemistry, we investigated eight types of tumor-infiltrating immune cells in the tumor nest and tumor-associated stroma as well as tumor expression of five cytokines in a uniform cohort of 956 patients with stage I lung ADC (478 each in training and validation cohorts). RESULTS: Although a high density of stromal forkhead box P3 (FoxP3) -positive cells was associated with shorter recurrence-free probability (RFP; P = .043), the relative proportion of stromal FoxP3 to CD3 was a stronger predictor of recurrence (5-year RFP, 85% for high v 77% for low ratio; P = .004). High expression of tumor interleukin-12 receptor ß2 (IL-12Rß2) was associated with better outcome (5-year RFP, 90% for high v 80% for low expression; P = .026), whereas high expression of tumor IL-7R was associated with worse outcome (5-year RFP, 76% for high v 86% for low expression; P = .001). In multivariate analysis, these immune markers were independently associated with recurrence. Although IL-7R remained significant for poor overall survival, all the markers remained prognostic for recurrence in patients with stages IA and IB disease as well as for patients with tumors ≤ 2 cm. CONCLUSION: Our investigation confirms the biologic and prognostic significance of the tumor immune microenvironment for patients with stage I lung ADC and provides support for its use to stratify clinical outcome and immunotherapeutic interventions.
Asunto(s)
Adenocarcinoma/inmunología , Adenocarcinoma/patología , Biomarcadores de Tumor/análisis , Complejo CD3/análisis , Factores de Transcripción Forkhead/análisis , Neoplasias Pulmonares/inmunología , Neoplasias Pulmonares/patología , Recurrencia Local de Neoplasia/inmunología , Receptores de Interleucina-12/análisis , Receptores de Interleucina-7/análisis , Adenocarcinoma/mortalidad , Adenocarcinoma/cirugía , Adenocarcinoma del Pulmón , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Inmunohistoquímica , Estimación de Kaplan-Meier , Neoplasias Pulmonares/mortalidad , Neoplasias Pulmonares/cirugía , Metástasis Linfática , Linfocitos Infiltrantes de Tumor/inmunología , Linfocitos Infiltrantes de Tumor/metabolismo , Masculino , Persona de Mediana Edad , Análisis Multivariante , Invasividad Neoplásica , Estadificación de Neoplasias , Valor Predictivo de las Pruebas , Medición de Riesgo , Factores de Riesgo , Análisis de Matrices TisularesRESUMEN
The interleukin-12 (IL-12) receptor (R) B2 gene acts as tumor suppressor in human acute and chronic B-cell leukemias/lymphomas and IL-12rb2-deficient mice develop spontaneously localized plasmacytomas. With this background, we investigated the role of IL-12R beta 2 in multiple myeloma (MM) pathogenesis. Here we show the following: (1) IL-12R beta 2 was expressed in primary MM cells but down-regulated compared with normal polyclonal plasmablastic cells and plasma cells (PCs). IL-6 dampened IL-12R beta 2 expression on polyclonal plasmablastic cells and MM cells. (2) IL-12 reduced the proangiogenic activity of primary MM cells in vitro and decreased significantly (P = .001) the tumorigenicity of the NCI-H929 cell line in SCID/NOD mice by inhibiting cell proliferation and angiogenesis. The latter phenomenon was found to depend on abolished expression of a wide panel of proangiogenic genes and up-regulated expression of the antiangiogenic genes IFN-gamma, IFN-alpha, platelet factor-4, and TIMP-2. Inhibition of the angiogenic potential of primary MM cells was related to down-regulated expression of the proangiogenic genes CCL11, vascular endothelial-cadherin, CD13, and AKT and to up-regulation of an IFN-gamma-related antiangiogenic pathway. Thus, IL-12R beta 2 directly restrains MM cell growth, and targeting of IL-12 to tumor cells holds promise as new therapeutic strategy.
Asunto(s)
Regulación Neoplásica de la Expresión Génica , Mieloma Múltiple/química , Receptores de Interleucina-12/análisis , Anciano , Anciano de 80 o más Años , Animales , Proliferación Celular/efectos de los fármacos , Humanos , Interleucina-12/farmacología , Ratones , Ratones SCID , Persona de Mediana Edad , Mieloma Múltiple/tratamiento farmacológico , Mieloma Múltiple/patología , Neovascularización Patológica/tratamiento farmacológico , Neovascularización Patológica/genética , Receptores de Interleucina-12/genética , Células Tumorales Cultivadas , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
Interleukin (IL)-23 plays a predominant role in the development of autoimmune diseases by inducing IL-17-producing helper T (Th17) cells. The receptor for IL-23 consists of a heterodimer composed of the IL-12 receptor beta1 (IL-12Rbeta1) and the IL-23 receptor (IL-23R), which is mainly expressed on Th17 cells. A recent study showed that macrophages express IL-23R mRNA and can be distinguished from microglia by IL-23R expression. However, in this study, we show by RT-PCR and immunocytochemistry that microglia express IL-23R and IL-12Rbeta1 mRNA and protein, respectively. Additionally, microglia expressed a functional receptor for IL-23, as IL-23 enhanced the Interferon (IFN)-gamma-induced signal transducer and activator of transcription (STAT)1 phosphorylation and chemokine production. Thus, IL-23R expression does not discriminate peripheral macrophages from microglia. Moreover, since microglia produce IL-23, it may function in an autocrine manner to recruit inflammatory cells by inducing chemokine production.